China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $5.32M
• Dividend Yield: N/A
• Average Volume (3M): 58.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -33.10%
• EPS Growth: 71.37%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 59
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 3,262,002
• 10 Day Avg. Volume: 54,435
• 30 Day Avg. Volume: 58,811
• PEG Ratio: -0.02
• Price to Book (P/B): 5.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.09
• Enterprise Value/Market Cap: 4.45
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: $1.50 ▼(-7.98%Downside)

The overall stock score is heavily impacted by financial performance challenges, including persistent losses and high leverage. Technical analysis further indicates a bearish trend, with all indicators pointing to weak stock momentum. Valuation is poor due to negative profitability and lack of dividends, making the stock unattractive to investors.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the production and sale of pharmaceutical products. The company's revenue model is based on the commercialization of its diverse portfolio of drugs, which includes both prescription and over-the-counter medications. Key revenue streams include sales to hospitals, pharmacies, and other healthcare institutions. Additionally, China Pharma Holdings may engage in strategic partnerships with other pharmaceutical companies to expand its product offerings and market reach, thereby enhancing its revenue potential. The company's earnings are influenced by factors such as product pricing, market demand, regulatory approvals, and its ability to innovate and introduce new products to the market.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces substantial financial challenges across income, balance sheet, and cash flow statements. Persistent losses, high leverage, and negative cash flows indicate operational and financial instability. Strategic improvements are necessary to enhance profitability, reduce debt reliance, and stabilize cash flows.

Income Statement

The income statement exhibits significant challenges, with negative gross profit and net income margins over the past years, indicating ongoing losses. Revenue growth is erratic, and both EBIT and EBITDA margins remain negative, reflecting operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating potential leverage risks. Return on equity is negative due to persistent losses. However, the equity ratio is moderately healthy, suggesting some asset stability despite financial distress.

Cash Flow

Cash flow analysis highlights a negative free cash flow and operating cash flow, indicating cash constraints. The ratios of operating and free cash flow to net income are unfavorable, emphasizing cash management difficulties and potential liquidity issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.14T	4.53M	7.01M	8.10M	9.64M	10.87M
	Gross Profit
-136.06B	-1.99M	-281.08K	-493.92K	349.27K	1.95M
	EBIT
-758.62B	-4.59M	-2.75M	-3.55M	-3.12M	-2.46M
	EBITDA
-758.62B	-1.96M	8.44K	-837.69K	230.34K	106.85K
	Net Income Common Stockholders
-785.58B	-4.74M	-3.08M	-10.22M	-3.94M	-3.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
412.69B	626.88B	1.42M	2.03M	4.86M	957.65K
	Total Assets
14.22T	15.07M	16.47M	17.78M	22.65M	21.12M
	Total Debt
1.41T	3.59M	4.63M	8.76M	12.49M	7.43M
	Net Debt
1.00T	2.96M	3.21M	6.73M	7.63M	6.47M
	Total Liabilities
7.25T	7.14M	9.01M	13.49M	16.63M	13.11M
	Stockholders Equity
6.97T	7.93M	7.45M	4.29M	6.02M	8.00M
Cash Flow		Free Cash Flow
-116.15B	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
	Operating Cash Flow
-57.82B	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
	Investing Cash Flow
-80.97B	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
	Financing Cash Flow
-70.03B	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Negative. The current price of 1.63 is below the 20-day moving average (MA) of 1.86, below the 50-day MA of 1.82, and below the 200-day MA of 2.11, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 41.27 is Neutral, neither overbought nor oversold. The STOCH value of 42.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
SBFM	47 Neutral	$7.06M	―	-21.17%	―	35.51%	95.44%
XBIO	43 Neutral	$4.65M	―	-53.16%	―	-1.56%	5.01%
CPHI	39 Underperform	$5.32M	―	-59.14%	―	-33.10%	71.37%
CELZ		$5.69M	―	-70.45%	―	―	―
SILO		$4.23M	―	-99.38%	―	―	―
ADTX		$3.07M	―	-191.76%	―	―	―

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.